SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer

SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer
- Seasoned team to drive forward pivotal trial for patients suffering from Tenosynovial Giant Cell Tumours (TGCT)
- Follows recent appointments of Professor Ton Logtenberg as non-executive Chairman and Ray Barlow as Chief Executive Officer
News provided by
Share this article
DUBLIN, Aug. 3, 2021 /PRNewswire/
 -- SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumours (TGCT), today announces the appointments of Axel Mescheder, MD as Chief Medical Officer and Broes Naeye, PhD as Chief Technology Officer, as it accelerates activities to support a registrational trial of emactuzumab in the USA and EU.

Related Keywords

United States ,Ireland ,Dublin ,Broes Naeye ,Gray Barlow ,Axel Mescheder ,Synox Therapeutics Limited ,Synox Senior Management Team ,Synox Therapeutics ,Tenosynovial Giant Cell Tumours ,Chief Medical Officer ,Chief Technology Officer ,Chief Medical ,Hoffmann La Roche ,Global Product Supply Lead ,Commercial Supply ,Chief Executive Officer ,Synox Senior Management ,Celleron Therapeutics ,Giant Cell Tumours ,ஒன்றுபட்டது மாநிலங்களில் ,ஐயர்ல்யாஂட் ,டப்ளின் ,ராய் பார்லோ ,தலைமை மருத்துவ அதிகாரி ,தலைமை தொழில்நுட்பம் அதிகாரி ,தலைமை மருத்துவ ,ஹாஃப்மேன் லா ரோச் ,வணிகரீதியானது விநியோகி ,தலைமை நிர்வாகி அதிகாரி ,